[To learn English]
Drugmaker Eli Lilly presented trial results to medical professionals on Saturday showing its next-generation obesity drug retatrutide curbed sleep apnea severity in addition to boosting weight loss and helping knee pain.
In a Phase 3 trial, Lilly found a weekly injection of retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60.6% in adults with obesity.
制药商礼来周六向医学专业人士公布的试验结果显示，其下一代减肥药retatrutide不仅能促进减重和缓解膝痛，还能抑制睡眠呼吸暂停的严重程度。
在一项三期试验中，礼来发现每周注射一次retatrutide可使肥胖成人的中度至重度阻塞性睡眠呼吸暂停严重程度降低60.6%。
LearnEnglish Leave a remark